Investors & Media

Corporate Overview

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.

Our lead clinical-stage candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-positive solid tumors. Data from our completed Phase 1 dose-escalation trial support the advancement of BDC-1001 into Phase 2 studies.

Bolt is also advancing BDC-3042, a proprietary myeloid modulating agonistic antibody targeting Dectin-2. BDC-3042 is designed to reprogram tumor-associated macrophages (TAMs) into immunostimulatory cells that enhance innate and adaptive anti-tumor immunity. Preclinical data support the advancement of BDC-3042 into the clinic in 2023.

News

May 25, 2023

Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual MeetingRead More

May 11, 2023

Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateRead More

April 26, 2023

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual MeetingRead More

View All News Releases

Events

June 3, 2023 at 9:00 AM EDT

2023 American Society of Clinical Oncology (ASCO) Annual Meeting Read More

April 17, 2023 at 1:30 PM EDT

American Association of Cancer Research (AACR) Annual Meeting 2023 Read More

March 7, 2023 at 2:50 PM EST

Cowen 43rd Annual Healthcare Conference Read More

View All Upcoming Events